---
title: "REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -1.13"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239193983.md"
datetime: "2025-05-07T20:15:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239193983.md)
  - [en](https://longbridge.com/en/news/239193983.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239193983.md)
generator: "portal-rs"
---

# REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -1.13

EPS: As of FY2025 Q1, the actual value is USD -1.13.

### Segment Revenue

-   **Research and Development Expenses**: $205.7 million for the three months ended March 31, 2025, compared to $118.0 million for the same period in 2024, representing a 74% increase.
-   **General and Administrative Expenses**: $35.0 million for the three months ended March 31, 2025, compared to $22.8 million for the same period in 2024, representing a 53% increase.

### Operational Metrics

-   **Net Loss**: $213.4 million for the three months ended March 31, 2025, compared to $116.0 million for the same period in 2024.
-   **Loss from Operations**: $240.8 million for the three months ended March 31, 2025, compared to $140.9 million for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $194.4 million for the three months ended March 31, 2025, compared to - $160.6 million for the same period in 2024.
-   **Net Cash Used in Investing Activities**: - $15.9 million for the three months ended March 31, 2025, compared to - $248.0 million for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $0.9 million for the three months ended March 31, 2025, compared to $0.8 million for the same period in 2024.

### Unique Metrics

-   **Stock-Based Compensation Expense**: $25.1 million for the three months ended March 31, 2025, compared to $16.2 million for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: Revolution Medicines, Inc. plans to advance its RAS(ON) inhibitors, including daraxonrasib, elironrasib, and zoldonrasib, through clinical development with ongoing and planned Phase 3 trials. The company expects to initiate pivotal combination studies in 2026.
-   **Non-Core Business**: The company is exploring collaborations, such as with Aethon Therapeutics, Inc. and Tango Therapeutics, Inc., to enhance its research and development efforts.

### Related Stocks

- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Nvidia Revenue Set to Increase 18X in 4 Years; Analyst Says 'Never in History' Has a Company Grown This Fast](https://longbridge.com/en/news/297126014.md)
- [Alphabet Is a 'Top 2027 Stock Pick,' Says Wolfe Research Analyst. Here's Why](https://longbridge.com/en/news/297186957.md)
- [Zhongji Innolight Fully Exercises Over-Allotment Option After Hong Kong IPO](https://longbridge.com/en/news/297095479.md)
- [Broadcom Stock (AVGO) Remains Wall Street's Pick Despite Google's Marvell Deal – Here's Why](https://longbridge.com/en/news/297093302.md)
- [Elon Musk's SPCX Now Accounts for 5% of Nvidia Revenue, Gene Munster Says: 'The Script Has Flipped'](https://longbridge.com/en/news/297157786.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**